Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. (Nasdaq: CGIP) is a biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The company leverages core expertise in T cell engagers, a therapeutic modality established in oncology that is now advancing into autoimmune disease treatment. Cullinan's clinical-stage pipeline is built on rigorous scientific approaches and purposeful innovation aimed at delivering new standards of care for patients.

The company's immunology programs include CLN-978, a CD19xCD3 bispecific T cell engager in Phase 1 development for systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's disease through the OUTRACE Program. Cullinan also develops velinotamig, a BCMAxCD3 bispecific T cell engager licensed from Chongqing Genrix Biopharmaceutical for autoimmune diseases outside Greater China, with initial clinical data expected in the fourth quarter of 2026.

In oncology, CLN-049 is a humanized FLT3xCD3 bispecific T cell engager in Phase 1 development for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The FDA granted Fast Track designation to CLN-049 in December 2025. Cullinan also collaborates with Taiho Pharmaceutical on zipalertinib, an orally available EGFR inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. In February 2026, Taiho completed a rolling submission of a new drug application seeking accelerated approval of zipalertinib for second-line treatment.

Cullinan's strategy focuses on exploring the broad potential of CLN-978 across autoimmune diseases, advancing CLN-049 for broad AML populations, and unlocking near-term non-dilutive financial benefits from zipalertinib. Under the Taiho collaboration, Cullinan is eligible to receive up to $130 million in regulatory milestone payments and 50% of future pre-tax profits from U.S. zipalertinib sales.

The company operates as a clinical-stage biopharmaceutical enterprise with a focus on T cell engager technology and strategic collaborations. Cullinan maintains a smaller reporting company status and is classified as a non-accelerated filer. The company's website is www.cullinanrx.com.